Intellia Therapeutics NASDAQ: NTLA is preparing for a potential U.S. launch of its hereditary angioedema gene-editing therapy, lonvo-z, while advancing late-stage studies in transthyretin amyloidosis, company executives said during a Jefferies fireside chat.
Intellia Therapeutics, Inc. ( NTLA ) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE November 12, 2026 10:00 AM EST Company Participants Jason Fredette - Vice President of Investor Relations & Corporate Communications John Leonard - President, CEO & Director Jing Marantz - EVP & Chief Medical Officer Maria Natale - Senior Vice President of Commercial Fred Cohen Conference Call Participants Marc Riedl Danny Cohn Joseph Thome - TD Cowen, Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Alec Stranahan - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Jeffrey Stith - Wells Fargo Securities, LLC, Research Division John Boyle - William Blair & Company L.L.C., Research Division Binita Shah Andy Chen - Wolfe Research, LLC Jasmine Fels - Barclays Bank PLC, Research Division Lydia Erdman Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Jade Montgomery Presentation Operator Good morning, everyone, and welcome to the Intellia Therapeutics HAE Investor Event.
Intellia Therapeutics NASDAQ: NTLA presented additional clinical data and outlined launch plans for lonvo-z, its investigational one-time gene-editing treatment for hereditary angioedema, as the company awaits a U.S. regulatory decision.
CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced highlights from its seven presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona. Intellia will host an investor webcast today at 10:00 a.m. ET to review certain data from the ACAAI presentations, share perspectives from key opinion leaders and discuss the company's preparations for a planned commercial launch of lonvo-z in HAE.
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026 at 8:30 a.m.
CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on November 1, 2026, it awarded inducement grants to three new employees as a material inducement to employment.
Intellia Therapeutics approaches a pivotal FDA decision in March 2027 for lonvo-z, potentially the first in vivo CRISPR therapy for hereditary angioedema. Lonvo-z's Phase 3 data showed ~87% attack reduction and a clean safety profile, positioning NTLA as a transformative one-time treatment in a crowded, high-cost market. Commercial success hinges on payer acceptance, physician adoption, and pricing strategy, with initial revenues likely modest but long-term potential significant if approved.
NTLA's Q3 loss deepens, while progress on its lonvo-z & nex-z clinical programs & a $400 million loan facility strengthen its pipeline & financial flexibility.
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.92 per share a year ago.
On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and multiple presentations next week at ACAAI 2026 Completed enrollment in MAGNITUDE-2 Phase 3 clinical trial in ATTRv-PN; advanced enrollment in MAGNITUDE in ATTR-CM Existing cash resources expected to fund operations at least into 2028 and well beyond lonvo-z's anticipated commercial launch, with recent term loan facility providing additional financial flexibility CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the third quarter ended September 30, 2026.